Herhope (Trastuzumab) Injection

Description

Description

This page contains brief details about the drug trastuzumab, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Date of Approval

Trastuzumab is a monoclonal antibody that was approved for its medical use on 25th September 1998.

Mechanism of Action of Trastuzumab

Trastuzumab Injection is a biological agent that acts as targeted drug therapy in cancer treatment. It is classified as a monoclonal antibody belonging to the class a HER2/neu receptor antagonists. HER2 or human epidermal growth factor receptor 2 is a protein present in high concentrations on the surface of cancer cells of the breast and gastric region. Trastuzumab Injection works by binding with these receptors, ultimately inhibiting the growth of cancer cells.

Uses of Trastuzumab

Trastuzumab Injection has been developed to treat solid tumors by injecting it as an intravenous infusion. Trastuzumab Injection has been approved to treat HER2 overexpressing breast cancer and stomach cancer (gastro-oesophageal Junction adenocarcinoma).

Trastuzumab Dosage available

Trastuzumab is available as multi dose vial injections in the doses 150 mg and 440 mg. It is intended for intravenous infusion only and not for IV push or bolus.